SCYX: scynexis.com Company Value to Net Income

Corporate emblem and logo of SCYNEXIS (SCYX)

SCYNEXIS, Inc. (SCYX) enjoys high trust among medical professionals due to its authority in treating complex infections. The team relies on an ethical approach, attracting leading microbiologists through long-term stock options. The price action reflects a PE multiple of -3.40. However, revenue potential is constrained by fierce competition in the antifungal segment and the possible release of low-cost generics, which creates certain commercial risks.

SCYNEXIS (SCYX) Price to Earnings Ratio: for the period 07/04/2022 - 11/10/2026

Comprehensive metric breakdowns and analytics for SCYNEXIS Inc (SCYX)

- price and consensus price forecast:
Stock Price Scynexis|SCYX - Consensus Target
- market capitalization information:
Market Value SCYNEXIS, Inc.|SCYX - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share SCYNEXIS|SCYX - Company Book Value|Capitalization to Book Value Ratio scynexis.com|SCYX - Company Total Assets
- debt and solvency information:
Aggregate Debt to Equity SCYNEXIS, Inc.|SCYX - Long-Term Debt to Capital|Current Liabilities to Capital Scynexis|SCYX - Company Aggregate Debts|Debt to Book Value SCYNEXIS, Inc.|SCYX - Company Long-Term Liabilities|Amount of Current Liabilities SCYNEXIS|Interim Coverage Ratio scynexis.com
- earnings and market multiples details:
SCYX - Company Net Income|Expected Net Profit SCYNEXIS, Inc.|SCYX - Price to Earnings Ratio|Price to Future Earnings Ratio Scynexis|SCYX - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio SCYNEXIS, Inc.|SCYX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters SCYNEXIS|SCYX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months scynexis.com|SCYX - Net earnings per share growth this year|Expected net earnings per share growth next year SCYNEXIS, Inc.
Summary company analysis:SCYX scynexis.com
Manufactured products of SCYNEXIS

For SCYNEXIS, Inc. (SCYX), a biotech developer of brexafemegril focused on the global infection therapy market, the price-to-earnings ratio serves as an indicator of innovation monetization efficiency. An analysis of the company's earnings multiple allows for an assessment of the premium paid for future successes in candidiasis treatment, revealing hidden systemic risks or asset undervaluation. The trend of this metric helps investors determine a safe entry point, preventing the purchase of overvalued securities.

Competing companies

P/E Multiple summittxinc.com|Price to Earnings Ratio MRNA (Moderna)|PCVX (Vaxcyte Inc) - Company Value to Net Income|P/E Multiple TARS (Tarsus Pharma)|Business Payback Period CorMedix Therapeutics (CRMD)|MCRB - Price to Earnings Ratio|SPRO (sperotherapeutics.com) - Price to Earnings Multiple|ANTX: P/E Multiple|Market Cap to Net Income PYPD (PolyPid)|LSB (YS Biopharma) - P/E Multiple|Market Cap to Earnings Iterum Therapeutics, plc ITRM|P/E Multiple PHGE|Price to Earnings Ratio soligenix.com SNGX|60 Degrees Pharmaceuticals, Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio OGEN (oragenics.com)|OpGen Corp - P/E Multiple